Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Sakar Healthcare's FCF Margin % or its related term are showing as below:
NSE:SAKAR'
s FCF Margin % Range Over the Past 10 Years
Min: -36.63 Med: -7.6 Max: 12.19
Current: 8.3
During the past 11 years, the highest FCF Margin % of Sakar Healthcare was 12.19%. The lowest was -36.63%. And the median was -7.60%.
NSE:SAKAR's FCF Margin % is ranked better than 66.04% of 963
companies
in the Drug Manufacturers industry
Industry Median: 2.57
vs NSE:SAKAR: 8.30
Sakar Healthcare FCF Margin % Related Terms
Sakar Healthcare FCF Margin % Historical Data
* Premium members only.
The historical data trend for Sakar Healthcare's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Sakar Healthcare's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sakar Healthcare FCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sakar Healthcare's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Sakar Healthcare's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sakar Healthcare (NSE:SAKAR) has a FCF Margin % of 0.00% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Sakar Healthcare and its competitors. According to the industry distribution chart, Sakar Healthcare ranks #327 out of 963 companies in the Drug Manufacturers industry, placing it in the top 34%.
Is Sakar Healthcare's FCF Margin % too high?
Sakar Healthcare's current FCF Margin % is 0.00%. Based on the distribution chart, Sakar Healthcare ranks #327 out of 963 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Sakar Healthcare has a GF Score™ of 60/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sakar Healthcare's FCF Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Sakar Healthcare ranks #327 out of 963 companies for FCF Margin %. This puts Sakar Healthcare in the upper half of its industry. The industry median FCF Margin % is 2.57. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.57, based on 963 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Sakar Healthcare and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sakar Healthcare's current FCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sakar Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Sakar Healthcare (NSE:SAKAR) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹540.00, compared to a current price of ₹904.45 — trading 67.5% above its estimated fair value. The current FCF Margin % is 0.00%. Sakar Healthcare's overall GF Score™ is 60/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Sakar Healthcare (NSE:SAKAR), the current FCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sakar Healthcare (NSE:SAKAR) Overvalued in 2026?
Based on GuruFocus' analysis, Sakar Healthcare stock appears to be overvalued.
The current stock price of ₹904.45 is trading 67.5% above its estimated GF Value™ of ₹540.00.
GuruFocus considers Sakar Healthcare to be Significantly Overvalued.
Key valuation signals for NSE:SAKAR:
FCF Margin %: 0.00%
GF Value™: ₹540.00 vs. price of ₹904.45 (67.5% above fair value)
No single metric tells the full story. See the NSE:SAKAR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sakar Healthcare Ltd is engaged in manufacturing Pharmaceutical products providing Liquid Orals, Cephalosporin Tablet, Capsule, Dry Powder Syrup, Dry Powder Injections, Liquid Injectables (SVP) in Ampoules and Vials & Lyophilized Injections. The company offers its products to Sri Lanka, the Philippines, Vietnam, Cambodia, Sudan, Myanmar, Mauritius, Costa Rica, Panama, El Salvador and Paraguay.
60GF Score
Get the complete analysis for NSE:SAKAR
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:SAKAR has been successfully added to your 
